Диссертация (1140195), страница 15
Текст из файла (страница 15)
J. Israels //Pharmacol. Sci. - 2003. - Vol. 93, № 4. - P 381 - 396.70. Mega, J.L. Cytochrome P450 polymorphisms and response to clopidogrel / J.L.Mega, S.L. Close, S.D. Wiviott // N. Engl. J. Med. – 2009. – Vol. 360. – P. 354 362.71. Mega, J. «Increasing Clopidogrel Based on CYP2C19 Genotype in Patients withCardiovascular Disease» [Электронный ресурс] / J.
Mega et al. // AHA Sci.sessions. - Nov 16, 2011. – Режим доступа: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_433744.72. Michelson, A. Platelet function testing in cardiovascular diseases / A.Michelson // Circulation. - 2005. - Vol. 10. - P. 132 – 137 (Suppl. 1).73. Montalescot, G.
A randomized comparison of high clopidogrel loading doses inpatients with non-ST-segment elevation acute coronary syndromes: the ALBION(Assessment of the Best Loading Dose of Clopidogrel to Blunt PlateletActivation, Inflammation and Ongoing Necrosis) trial / G. Montalescot, G.Sideris, C. Meuleman // JACC. - 2006. - Vol. 48, №5. - P. 931 - 938.74. Munger, M. Atherothrombosis: epidemiology, pathophysiology, and prevention/ M. Munger, D. Hawkins // J. Am.
Pharm. Assos. - 2004. - Vol. 44, № 2 (Suppl.1). - P. S5 - S12.75. Müller, I. Prevalence of clopidogrel non-responders among patients with stableangina pectoris scheduled for elective coronary stent placement / I. Müller, F.Besta, C. Schulz // Thromb. Haemost. - 2004. - Vol. 89. - P. 783 – 787.76. Patrono, C. Platalet Activation and Inhibition in Unstable Coronary Syndromes/ C. Patrono, G. Renda // Am. J.
Cardiol. - 1997. - Vol. 80, № 5 A. - P 17E -20E.77. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomized clinical trials / E. Boersma, R.A. Harrington,D.J. Moliterno et al. // Lancet. – 2002. - Vol. 359. - P. 189-198.12678. Platelet inhibition by aspirin is diminished in patients during carotid surgery: aform of transient aspirin resistance? / D.A.
Payne, C.I. Jones, P.D. Hayes et al. //Thromb. Haemost. – 2004. - Vol. 92. - P. 89 - 96.79. Peto, R. Randomized trial of prophylactic daily aspirin in British mail doctors /R. Peto et al. // BMJ. – 1988. – Vol. 926. – P. 313 - 316.80. Pharmacogenetic Testing for Clopidogrel Using, the Rapid INFINITI AnalyzerHarvey White, Jamie Voss, John Ormiston // JACC: Cardiovascular Intervention.- 2009. - Vol. 2.
– P. 11.81. Protective effects of aspirin against acute myocardial infarction and death inmen with unstable angina. Results of a Veterans Administration CooperativeStudy / H.D. Lewis, J.W. Davis, D.G. Archibald et al. // N. Engl. J. Med. - 1983Aug 18. – Vol.
309, № 7. – P. 396 – 403.82. Randomized double-blind assessment of the ONSET and OFFSET of theantiplatelet effects of ticagrelor versus clopidigrel in patients with stablecoronary artery disease: the ONSET/OFFSET study / P.A. Gurbel, K.P. Bliden,K. Butler et al. // Circulation. – 2009. – Vol. 120, № 25. – P. 2577-2785.83. Ridker, P.M. A randomized trial of low-dose aspirin in primary prevention ofcardiovascular disease in women / P.M. Ridker, N.R.
Cook, I.M. Lee // N. Engl.J. Med. - 2005. - Vol. 352. - P. 1293 – 1304.84. Rocca, B. Determinants of the interindividual variability in response toantiplatelet drugs / B. Rocca, C. Patrono // J. Thromb. Haemost. - 2005. - Vol. 3,№ 8. - P. 1597 - 1602.85. Saw, J. Lack of adverse clopidogrel-atorvastatin clinical interaction fromsecondary analysis of a randomized, placebo-controlled clopidogrel trial / J. Saw,S. Steinhubl, P. Berger // Circulation. - 2003.
- Vol. 108, № 8. - P 921-924.86. Serebruany, V. Statins do not affect platelet inhibition with clopidogrel duringcoronary stenting / V. Serebruany, A. Malinin, K. Callahan // Atherosclerosis. 2001. - Vol. 159, № 1. - P. 239 - 241.12787. Sibbing, D. Cytochrome P450 2C19 loss-of-function polymorphism and stentthrombosis following percutaneous coronary intervention / D. Sibbing, J.Stegherr, W. Latz // Eur. Heart J. – 2009.
– Vol. 30. – P. 916 - 922.88. Siller-Matula, J.M. Pharmacokinetic, pharmacodynamic and clinical profile ofnovel antiplatelet drugs targeting vascular diseases / J.M. Siller-Matula, J.Krumphuber, B. Jilma // Br. J. Pharmacol. – 2010. – Vol. 159, № 3 – P. 502 517.89. Sirotkina, O. The new single nucleotide polymorphisms of ADP receptor P2Y12gene affected platelet aggregation and myocardial infarction development werefound in Russia / O.
Sirotkina, A. Novikova, T. Vavilova // J. Thromb. Haemost.- 2005. - Vol. 3 (Suppl 1). - P. 0980.90. Steering Committee of the Physician’ Health Study Research Group. Finalreport of the aspirin component of the ongoing Physician’ Health Study // NewEngland Journal of Medicine. – 1989. - Vol. 321. – P. 129 - 135.91. Steinhubl, S. Resistance to antiplatelet resistance is it justified? / S.
Steinhubl, R.Charnigo, D. Moliterno // JACC. - 2005. - Vol. 42, № 11. - P. 1757 – 1758.92. Stone, G. Long-term care after percutaneous coronary intervention: focus on therole of antiplatelet therapy / G. Stone, H. Aronow // Mayo Clin. Proc. - 2006. Vol. 81, № 5. - P. 641 – 652.93. Storey, R.F. Current Pharmaceutical Design – 2006 / R.F. Storey // JACC. –2007.
– Vol. 50. – P. 1844.94. Sun, Ah. Association of polymorphisms in thromboxane A2 receptor andthromboxane A synthase 1 with cerebral infarction in a Korean population / AhSun, Lae Byung, Jeong Ho. // BMB. - 2009. - P. 200 – 205.95. Taubert, D.
Pharmacokinetics of clopidogrel after administration of a highloading dose / D. Taubert, A. Kastrati, S. Harlfinger // Thrombosis Haemost. 2004. - Vol. 92, № 2. - P. 311 - 316.96. The Medical Research Group Council’s General Practice Research Framework.Thrombosis prevention trial of low intense oral anticoagulants with warfarin and128low-dose aspirin in primary prevention of ischemic heart disease in men atincreased risk // Lancet. - 1998. - Vol.
351. - P. 233 – 241.97. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes / L.Wallentin, R. C. Becker, A. Budaj et al. // N. Engl. J. Med. – 2009. – Vol. 361,№ 11. – P. 1045 - 1057.98. Underuse of aspirin in a referral population with documented coronary arterydisease / R. Califf, E. DeLong, T.
Ostbye et al. // Am. J. Cardiol. - 2002. - Vol.89, № 6. - P. 653 – 661.99. Vessel, plaque, and lumen morphology after transluminal balloon angioplasty.Quantitative study in distended human arteries / R. Lyon, C. Zarins, C. Lu et al.// Arteriosclerosis. - 1987. - Vol. 7, № 3. - P. 306 - 314.100.Wallentin, L.C. Aspirin after episode of instable coronary artery disease:long – term effects on the risk of myocardial infarction, occurrence of severeischemia and necesserity of revascularization / L.C. Wallentin, and RISC // J. ofAmerican College of Cardiol. – 1991. – Vol.
18. – P. 1587 – 1593.101.Wenbin Z. The relationship between P2Y12 gene polymorphisms andclopidogrel resistance in patients with coronary heart disease / Zhang Wenbin,Chen Xiaoyan, Zhang Xinxia // Heart. – 2012. - Vol. 98. - P. 105.102.Yee, D. Aggregometry detectsplatelet hyperreactivity in healthyindividuals / D. Yee, C. Sun, A. Bergeron // Blood. - 2005. - Vol. 106, № 8. - P.2723 - 2729.103.Yong, G. Randomized trial comparing 600-with 300-mg loading dose ofclopidogrel in patients with non-ST elevation acute coronary syndromeundergoing percutaneous coronary intervention: results of the PlateletResponsiveness to Aspirin and Clopidogrel and Troponin Increment afterCoronary intervention in Acute coronary Lesions (PRACTICAL) Trial / G.Yong, J.
Rankin, L. Ferguson // American Heart Association. - 2009. - Vol. 157,№ 1. - P. 601 - 609..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
